L’Institut Mérieux has sold its subsidiary ABL Lyon (renamed to Active Biomarkers) to Turenne Santé

Paris – CFI France is pleased to announce that they acted as exclusive financial advisor to l’Institut Mérieux in the sale of its subsidiary ABL Lyon (renamed to Active Biomarkers) to Turenne Santé.

L’Institut Merieux was founded in 1897 in Lyon, is a family holding company dedicated to global public health around the world.

ABL Lyon, now renamed Active Biomarkers, is an integrated bioanalytical laboratory with biomarker and cell-based assay testing capabilities, specialized in well-targeted therapeutic fields such as oncology, infectious diseases, inflammatory pathologies and neurodegenerative diseases.

The company supports multiple biopharmaceutical companies in their clinical research programs (Phases I to IV).

With the support of Turenne Santé, Active Biomarkers will pursue its dynamic growth by gaining new customers. It will also enable to boost significantly its production and R&D capacity, to strengthen its portfolio of proprietary assays, and to evaluate external growth opportunities.

The transaction was announced on 5 November 2020.